Website: [www.locus-bio.com](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttp-253A-252F-252Fwww.locus-2Dbio.com-26data-3D01-257C01-257Cjoseph.nixon-2540locus-2Dbio.com-257C47e01452c96e4eee23b208d737ca5c3f-257C16b58b1823bc474d8293aed343cf729f-257C0-26sdata-3DU3XBt0UdbRBoj6fBCQnOtg3864Z8bJ4BcSZ4IzePi4Q-253D-26reserved-3D0%26d%3DDwMFAg%26c%3DQbuapHRvbn0JdC8vTVkPHg%26r%3DBRvmOOkD1Z5gYGCwq77Jdw%26m%3DDhWSeLxO8MO2VbhjVACXZiP-udL4GX_B-PhjlLXAtZU%26s%3D3b05G5dqRroGq5HtVzEuBWNthuE2o-D8-sG7eeoi5Vg%26e%3D&data=01%7C01%7Cjoseph.nixon%40locus-bio.com%7Cb658034986174c57194108d7917b5843%7C16b58b1823bc474d8293aed343cf729f%7C0&sdata=lPI05zxjG51SLlmyb%2BEMdrpRlefRcSP4tHzFiJoGX4E%3D&reserved=0)

**25 Word Summary**

Locus is a clinical-stage biotechnology company developing CRISPR-enhanced precision antibacterial products that kill target pathogens while leaving non-target bacteria unharmed.

**50 Word Summary**

Locus is a clinical-stage biotechnology company developing CRISPR-enhanced precision antibacterial products (crPhage™) to address critical unmet medical needs in bacterial infections and high-value microbiome indications. The Locus platform combines CRISPR-Cas3, which degrades targeted DNA within a bacterial cell, with bacteriophage to kill target pathogens while leaving non-target bacteria unharmed.

**100 Word Summary**

Locus Biosciences is a clinical-stage biotechnology company developing CRISPR-enhanced precision antibacterial products (crPhage™) to address critical unmet medical needs in bacterial infections and microbiome indications in oncology, immunology and central nervous system therapeutic areas. The Locus platform combines CRISPR-Cas3, which shreds target DNA within a bacterial cell, with bacterial viruses called bacteriophage to specifically kill target pathogens while leaving non-target bacteria (i.e., the rest of the patient’s microbiome) unharmed. Locus has strong backing from partners, having signed a collaboration agreement with Johnson & Johnson worth up to $818 million in upfront, development, and commercial milestones and has signed contracts with BARDA that could yield up to $77 million in revenue to Locus and with CARB-X for up to $12 million. The company launched its first clinical trial in 2020 and expects to read out top-line data for that trial in Q1 2021.

**Highlights of Company Achievements:**

* Contract with the global non-profit, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to fund up to $11.6 million of a $14 million program for development of LBP-KP01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product targeting the bacterial pathogen *Klebsiella pneumoniae* (*K. pneumoniae*) through Phase 1 of clinical development.
* Contract with the Biomedical Advanced Research and Development Authority (BARDA) to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product that will target *Escherichia coli* (*E. coli*) bacteria causing recurrent urinary tract infections (UTIs). The contract provides up to $77 million in funding to Locus as part of a $144 million program to support Phase 2 and Phase 3 clinical trials and other activities required to seek marketing approval from the U.S. Food and Drug Administration (FDA) for LBP-EC01.
* First-in-human, placebo-controlled Phase 1b clinical trial of a CRISPR Cas3-enhanced bacteriophage (crPhage™ product targeting *E. coli* in UTIs) enrolled its first patient in January 2020, with an estimated topline data readout in Q1 2021
* IND for lead asset (crPhage™ product targeting *E. coli*) cleared November 2019
* Executed an [$818m collaboration](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fwww.locus-2D2Dbio.com-5Fpress-2D2Dreleases-5F-2526d-253DDwMFAg-2526c-253DQbuapHRvbn0JdC8vTVkPHg-2526r-253DBRvmOOkD1Z5gYGCwq77Jdw-2526m-253DDhWSeLxO8MO2VbhjVACXZiP-2DudL4GX-5FB-2DPhjlLXAtZU-2526s-253DbsAGDDCvwVW5qdv4aLmmnqaH7gnICs5gYNRdDr4HQ18-2526e-253D-26data-3D01-257C01-257Cdave-2540locus-2Dbio.com-257C38b9fff333a5480190e308d746e93cdc-257C16b58b1823bc474d8293aed343cf729f-257C0-26sdata-3DThytWRRfPY3hMKLmz6wyxXQP-252FE02-252F6mftbQ-252FyrxOt1M-253D-26reserved-3D0%26d%3DDwMGaQ%26c%3DQbuapHRvbn0JdC8vTVkPHg%26r%3DBRvmOOkD1Z5gYGCwq77Jdw%26m%3Diz0IoS5fwMuJvdaxrUfN3ErCQi5j9DZV6lq7DYh_CB0%26s%3D4AGXUkKZruuoNPqKN1FH11BZuSQAOL-tGVoGSkNAO6Y%26e%3D&data=01%7C01%7Cjoseph.nixon%40locus-bio.com%7Cb658034986174c57194108d7917b5843%7C16b58b1823bc474d8293aed343cf729f%7C0&sdata=cGM50I5beJYclE6e3gmZ3Z3ywYdWiy7jtpgdolN5dR0%3D&reserved=0) ($20m upfront) with Johnson & Johnson on company’s second and third pipeline assets in January 2019
* Selected by FierceBiotech for the [2019 Fierce 15](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fwww.fiercebiotech.com-5Fspecial-2D2Dreport-5Ffiercebiotech-2D2Ds-2D2D2019-2D2Dfierce-2D2D15-2526d-253DDwMFAg-2526c-253DQbuapHRvbn0JdC8vTVkPHg-2526r-253DBRvmOOkD1Z5gYGCwq77Jdw-2526m-253DDhWSeLxO8MO2VbhjVACXZiP-2DudL4GX-5FB-2DPhjlLXAtZU-2526s-253Dk0ecH2pQiecLTuDsPVjXN1xAd-5F2zzT0eoatrd8ww3dg-2526e-253D-26data-3D01-257C01-257Cdave-2540locus-2Dbio.com-257C38b9fff333a5480190e308d746e93cdc-257C16b58b1823bc474d8293aed343cf729f-257C0-26sdata-3DfWq55fABDAfqzlUz9EW5uOpOdrQmpMsxxt9fl5bto-252Fg-253D-26reserved-3D0%26d%3DDwMGaQ%26c%3DQbuapHRvbn0JdC8vTVkPHg%26r%3DBRvmOOkD1Z5gYGCwq77Jdw%26m%3Diz0IoS5fwMuJvdaxrUfN3ErCQi5j9DZV6lq7DYh_CB0%26s%3DQ66kdDUIKq0TUJvGUpFZnsGh6wxPMluIJbpI9FLPxL0%26e%3D&data=01%7C01%7Cjoseph.nixon%40locus-bio.com%7Cb658034986174c57194108d7917b5843%7C16b58b1823bc474d8293aed343cf729f%7C0&sdata=tsa0%2F%2B6mTvt5WvS%2BwBcr5NsvHgIOle6AyD6RWdpw0Lg%3D&reserved=0) which recognizes the best emerging biotechnology companies in the US and Europe and by CNBC for its [Upstart 100](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.cnbc.com%2F2019%2F11%2F12%2F100-of-the-worlds-most-promising-start-ups-to-watch-in-2019.html&data=01%7C01%7Cjoseph.nixon%40locus-bio.com%7Cb658034986174c57194108d7917b5843%7C16b58b1823bc474d8293aed343cf729f%7C0&sdata=HlRzgLT6e0O9Y9pgY8iZ8TbXHVcC6gQNj%2FOnkOsc4%2Fo%3D&reserved=0) list of the 100 most promising pre-Series B startups in the world
* Completed construction of cGMP manufacturing facility in May 2019 in Research Triangle Park, NC to produce clinical trial materials for its lead asset; facility expansion is underway to support Phase 2 to commercial scale manufacturing
* [Acquired assets of EpiBiome](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fwww.locus-2D2Dbio.com-5Flocus-2D2Dbiosciences-2D2Dacquires-2D2Depibiomes-2D2Dhigh-2D2Dthroughput-2D2Ddiscovery-2D2Dplatform-2D2Dto-2D2Dcreate-2D2Dthe-2D2Dworlds-2D2Dleading-2D2Dcrispr-2D2Dengineered-2D2Dbacteriophage-2D2Dcompany-5F-2526d-253DDwMFAg-2526c-253DQbuapHRvbn0JdC8vTVkPHg-2526r-253DBRvmOOkD1Z5gYGCwq77Jdw-2526m-253DDhWSeLxO8MO2VbhjVACXZiP-2DudL4GX-5FB-2DPhjlLXAtZU-2526s-253DVn58hDHG1thCii-5FjGvsnfcl1eb9vr58vdzOBkFBPN-2Dg-2526e-253D-26data-3D01-257C01-257Cdave-2540locus-2Dbio.com-257C38b9fff333a5480190e308d746e93cdc-257C16b58b1823bc474d8293aed343cf729f-257C0-26sdata-3DfXshBJ7jR-252F0xq7E-252B-252FhP3yc5w8nnxvZX4bri362s3OsQ-253D-26reserved-3D0%26d%3DDwMGaQ%26c%3DQbuapHRvbn0JdC8vTVkPHg%26r%3DBRvmOOkD1Z5gYGCwq77Jdw%26m%3Diz0IoS5fwMuJvdaxrUfN3ErCQi5j9DZV6lq7DYh_CB0%26s%3DQGvzO4XcFnkUYBzflI97ew0d7Npp74zSjhAFA-ywuzY%26e%3D&data=01%7C01%7Cjoseph.nixon%40locus-bio.com%7Cb658034986174c57194108d7917b5843%7C16b58b1823bc474d8293aed343cf729f%7C0&sdata=%2FglLaVOOcml%2BL2F26vHyLxzCXht2ToHSYC0L3SudPpk%3D&reserved=0) in July 2018 to add automated robotics and high-throughput screening of bacteriophage to the Locus synthetic biology platform
* Raised [$19m Series-A](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fwww.locus-2D2Dbio.com-5Flocus-2D2Dbiosciences-2D2Dcloses-2D2D19-2D2Dmillion-2D2Dseries-2D2Da-2D2Dled-2D2Dby-2D2Dartis-2D2Dventures-2D2Dfor-2D2Dcrispr-2D2Dcas3-2D2Dantimicrobials-5F-2526d-253DDwMFAg-2526c-253DQbuapHRvbn0JdC8vTVkPHg-2526r-253DBRvmOOkD1Z5gYGCwq77Jdw-2526m-253DDhWSeLxO8MO2VbhjVACXZiP-2DudL4GX-5FB-2DPhjlLXAtZU-2526s-253Dkkr4bDrAROdKYG1uZgO7UaqfOoPixvFyQ6nKjjk287E-2526e-253D-26data-3D01-257C01-257Cdave-2540locus-2Dbio.com-257C38b9fff333a5480190e308d746e93cdc-257C16b58b1823bc474d8293aed343cf729f-257C0-26sdata-3DkPsVYvGkCuveYy2Ogc5bF6Q1flsYqkIguXKdUuqpVWk-253D-26reserved-3D0%26d%3DDwMGaQ%26c%3DQbuapHRvbn0JdC8vTVkPHg%26r%3DBRvmOOkD1Z5gYGCwq77Jdw%26m%3Diz0IoS5fwMuJvdaxrUfN3ErCQi5j9DZV6lq7DYh_CB0%26s%3DqUGeO-9vJ2M7OPJ0h4UMyMOIJOiuFhNBo8ofgBKWnNM%26e%3D&data=01%7C01%7Cjoseph.nixon%40locus-bio.com%7Cb658034986174c57194108d7917b5843%7C16b58b1823bc474d8293aed343cf729f%7C0&sdata=WEKdJgvpu0EnVcULxYqBKK4tuAqBB1hGs73OJAF%2B78U%3D&reserved=0) funding round in September of 2017 led by ARTIS Ventures & Tencent Holdings